Regional differences in the global burden of age-related macular degeneration

被引:0
作者
Xiayan Xu
Jing Wu
Xiaoning Yu
Yelei Tang
Xiajing Tang
Xingchao Shentu
机构
[1] The Second Affiliated Hospital of Zhejiang University,Department of Ophthalmology
[2] College of Medicine,undefined
来源
BMC Public Health | / 20卷
关键词
Macular degeneration; Disability-adjusted life years; Global burden of disease;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 138 条
  • [11] Li Y(2018)Global, regional and national incidence, prevalence, and years lived with disability for 354 diseases and injuries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 392 1789-1762
  • [12] Xu L(2018)Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of Disease study 2017 Lancet 392 1859-567
  • [13] Jonas JB(1997)Learning and understanding the Kruskal-Wallis one-way analysis-of-variance-by-ranks test for differences among three or more independent groups Phys Ther 77 1755-1641
  • [14] Yang H(2005)Anti-macular degeneration agents Ophthalmol Clin N Am 18 561-1411
  • [15] Ma Y(2014)Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD Br J Ophthalmol 98 1636-2309
  • [16] Li J(2012)Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 1399-271
  • [17] Li Y(2013)Ranibizumab versus Bevacizumab for Neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial Ophthalmology 120 2300-1267
  • [18] Xu L(2013)A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration Br J Ophthalmol 97 266-1398
  • [19] Wang YX(2013)Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 1258-1908
  • [20] You QS(2012)Ranibizumab and Bevacizumab for treatment of Neovascular age-related macular degeneration: 2-year results Ophthalmology 119 1388-2232